First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results